Chemical formula: C₂₃H₂₇N₅O₇S Molecular mass: 517.555 g/mol PubChem compound: 43672
Piperacillin interacts in the following cases:
The inactivation of tobramycin and gentamicin by piperacillin has been demonstrated in patients with severe renal impairment.
Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid substance toxicity.
Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Due to their similar mechanisms of action, it is expected that the neuromuscular blockade produced by any of the non-depolarising muscle relaxants could be prolonged in the presence of piperacillin.
There are no or a limited amount of data from the use of piperacillin in pregnant women.
Studies in animals have shown developmental toxicity, but no evidence of teratogenicity, at doses that are maternally toxic.
Piperacillin cross the placenta. Piperacillin should only be used during pregnancy if clearly indicated, i.e. only if the expected benefit outweighs the possible risks to the pregnant woman and foetus.
Piperacillin is excreted in low concentrations in human milk; Women who are breast-feeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.
No studies on the effect on the ability to drive and use machines have been performed.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.